Governance Quoin Pharmaceuticals, Ltd.

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 08/07/2025 BST			5-day change	1st Jan Change
8.730 ^USD	-1.69%		-5.37%	-61.67%

07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
06-26	Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	CI

Executive Committee: Quoin Pharmaceuticals, Ltd.

Manager

Positions heldSince

Michael Myers

63 year

Chief Executive Officer	27/10/2021
Founder	04/03/2018

Denise Carter

56 year

Chief Operating Officer	27/10/2021
Founder	04/03/2018

Gordon Dunn

61 year

Comptroller/Controller/Auditor	31/10/2021
Director of Finance/CFO	31/10/2021

Composition of the Board of Directors: Quoin Pharmaceuticals, Ltd.

Director

CommitteesSince

Michael Myers

63 year

Audit Committee	31/10/2022
Nominating Committee	31/10/2022
Compensation Committee Chair	31/10/2022

Joseph Cooper

67 year

Audit Committee	27/10/2021
Governance Committee	27/10/2021
Nominating Committee	27/10/2021

Natalie Leong

40 year

Audit Committee	27/10/2021
Governance Committee Chair	27/10/2021
Nominating Committee Chair	27/10/2021

Anthony Culverwell

69 year

Compensation Committee	21/02/2022
Audit Committee Chair	21/02/2022

Michael Sember

Compensation Committee

27/10/2021

Dennis Langer

74 year

Compensation Committee Chair

27/10/2021

Denise Carter

56 year

Director/Board Member

27/10/2021

Latest Appointments: Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	07-08	RE
Cellect Biotechnology Ltd. Announces Resignation of Sivan Rahamin as External Director on October 19, 2020	13/10/20	CI
Cellect Biotechnology Ltd. Announces Resignation of Kasbian Nuriel Chirich from Chairman of the Board of Directors	10/01/20	CI
Cellect Biotechnology Ltd. Announces Resignation of Ruhama Avraham as A Director	22/08/19	CI
Cellect Biotechnology Ltd. Announces Michael Berelowitz Not to Stand for Re-Election as Member of the Board of Directors	06/06/19	CI
Ruth Ben Yakar Resigns as Director of Cellect Biotechnology Ltd	22/03/19	CI
Cellect Biotechnology Ltd. Elects Jonathan Burgin as External Director for Three-Year Term Ending October 24, 2021	25/10/18	CI

More news

Former Officers and Directors: Quoin Pharmaceuticals, Ltd.

Insider

Positions held

SinceUntil

Peter A. Lankau

Director/Board Member

Age distribution of managers

Parity Men Women

Male	6
Female	2

Of which Executive Committee

Male	2
Female	1

Of which Directors

Male	5
Female	2

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-13 - Q2 2025 Earnings Release (Projected)

More about the company